An MHRA-licensed GLP-1 medication that achieved up to 15% body weight reduction in the STEP clinical trials. Our comprehensive programme, combining medication with lifestyle support, has shown an average of 21.55% weight loss in internal programme data. Individual results may vary.

Wegovy is a prescription-only weight loss medication containing semaglutide, manufactured by Novo Nordisk. It's a once-weekly subcutaneous injection specifically licensed in the UK for weight management in adults with obesity or overweight with weight-related health conditions.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists. These medications mimic a naturally occurring hormone in your body that regulates appetite, food intake, and blood sugar levels. By activating GLP-1 receptors, Wegovy helps you feel fuller for longer, reduces cravings, and makes it easier to stick to a healthy eating plan.
In November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Wegovy for weight management in the UK. In the STEP clinical trial programme, participants achieved an average weight loss of approximately 15% when combined with lifestyle changes. Individual results may vary.
Wegovy works by mimicking GLP-1, a naturally occurring hormone that regulates your appetite and food intake through multiple mechanisms.
Signals your brain's appetite centres to reduce hunger and cravings, making it easier to eat less without feeling deprived.
Delays stomach emptying so food stays in your stomach longer, helping you feel fuller for longer after meals.
Stimulates insulin release and suppresses glucagon, helping maintain steady energy levels throughout the day.
Clinical trials show Wegovy reduces the risk of major cardiovascular events by 20% in people with heart disease.
In the landmark STEP 1 clinical trial involving over 1,900 adults with obesity, participants taking Wegovy achieved remarkable results:
Average body weight loss
Compared to 2.4% with placebo over 68 weeks
Lost at least 5% body weight
Clinically meaningful weight loss threshold
Reduced cardiovascular risk
Lower risk of heart attacks and strokes (SELECT trial)
TLWLC Results Go Further
Our patients average 21.55% total body weight loss—53% more than medication alone—thanks to our comprehensive programme combining Wegovy with personalised nutrition and lifestyle coaching.
Weeks 1-4
Appetite reduction begins. Most patients notice decreased hunger and food noise within 2 weeks.
Weeks 5-12
Steady weight loss of 1-2 lbs per week as dose increases. Clothes start fitting looser.
Months 3-6
Significant weight loss typically 8-12% of starting weight. Health markers improve.
12+ Months
Maximum weight loss achieved. Focus shifts to maintenance and sustainable habits.
Not sure if Wegovy is right for you? Our clinical team will assess your eligibility during your free consultation.
While most people seek Wegovy for weight loss, the medication delivers several additional health benefits that may be equally important for your long-term wellbeing.
Wegovy holds unique status as the only weight loss medication specifically licensed to reduce cardiovascular risk. In the SELECT clinical trial of over 17,600 people with heart disease, Wegovy reduced the risk of heart attacks, strokes, and cardiovascular death by 20%.
Who benefits most from cardiovascular protection:
Wegovy delivers powerful blood sugar improvements, even though it isn't licensed specifically for Type 2 diabetes treatment (Ozempic, containing the same active ingredient, is the version licensed for diabetes).
How Wegovy helps manage blood sugar:
Start with a single month or save with our 3-month plan. All plans include free delivery and clinical support.
Try Wegovy with no commitment. Perfect if you're new to GLP-1 treatment.
From £144
Starting dose (0.25mg)
Save £10/month with our most popular plan. Includes dose titration.
From £402
£134/month (save £10/month)
💡 Your dose usually increases monthly as part of your titration. Our assessment will recommend the right starting point for you.
| Dosage | 1 Month | 3 Month (per month) |
|---|---|---|
| 0.25mg (Starting) | £144 | £134(save £10) |
| 0.5mg | £169 | £159(save £10) |
| 1mg | £189 | £179(save £10) |
| 1.7mg | £219 | £209(save £10) |
| 2.4mg (Maintenance) | £239 | £229(save £10) |
Free assessment • Results in minutes • No obligation
Wegovy uses a gradual dose escalation to minimise side effects and allow your body to adjust.
These typically improve as your body adjusts (usually within a few weeks):
Contact your doctor or our clinical team immediately if you experience:
Our clinical team is available around the clock to answer questions and address any concerns about side effects. We monitor your progress throughout your journey and can adjust your treatment plan if needed.